Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients

References

• Jadoul M, Barril G. Hepatitis C in hemodialysis: Epidemiology and prevention of hepatitis C virus transmission. Contrib Nephrol. 2012;176:35–41
   PubMed Web of Science ®Google Scholar
• Fissell R, Bragg-Gresham J, Woods J, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2004;65:2335–2342
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Messa P, Martin P. Health-related quality of life in dialysis patients with HCV infection. Int J Artif Organs. 2009;32:473–481
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: A link with cardiovascular mortality? J Viral Hepat. 2012;19:601–607
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155
   PubMed Web of Science ®Google Scholar
• Carvalho-Filho RJ, Feldner ACCA, Silva AEB, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol. 2015;21(2):408–422
   PubMed Web of Science ®Google Scholar
• Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11(3):172--182
   PubMed Web of Science ®Google Scholar
• Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165–1171
   PubMed Web of Science ®Google Scholar
• Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014;6(6):419–425
   PubMedGoogle Scholar
• Kidney disease: Improving global outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008;73(Suppl 109):S1–S99
   Google Scholar
• Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study. Blood. 2010;116:343–353
   PubMed Web of Science ®Google Scholar
• Liu C, Huang C, Liu C, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial. Ann Intern Med. 2013;159:729–738
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P, Martin P. Antivirological therapy (pegylated interferon plus ribavirin) of hepatitis C in dialysis patients: Meta-analysis of clinical studies. J Viral Hepat. 2014;21:681–689
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Akiba T, Nitta K, et al. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study. Ther Apher Dial. 2014;18(6):603–611
   PubMed Web of Science ®Google Scholar
• Fabrizio F, Messa P, Martin P. Recent advances on hepatitis C virus in dialysis population. Kidney Blood Press Res. 2014;39:260–271
   PubMed Web of Science ®Google Scholar
• Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med. 2010;3:1–13
   PubMedGoogle Scholar
• Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212–223
   PubMed Web of Science ®Google Scholar
• Sikole A, Dzekova P, Selja N, et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Ren Fail. 2007;29(8):961–966
   PubMed Web of Science ®Google Scholar
• Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012;9:406–417
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced virological clearance. Nature. 2009;461:399–401
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–1109
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology. 2010;138:1338–1345
   PubMed Web of Science ®Google Scholar
• Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–1898
   PubMed Web of Science ®Google Scholar
• Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978–988
   PubMed Web of Science ®Google Scholar
• Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired virological kinetics and therapeutic response. Hepatology. 2012;56:444–454
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Traub N. Sustained virological response to antivirological therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis. 2011;52:889–900
   PubMed Web of Science ®Google Scholar
• Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6(2):e17232
   PubMed Web of Science ®Google Scholar
• Köse S, Senger SS, Ersan G, Cavdar G. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C. Clin Exp Nephrol. 2013;17:115–119
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang CF, et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol. 2014;60(2):253–259
   PubMed Web of Science ®Google Scholar
• Domagalski K, Pawlowska M, Tretyn A, et al. Association of IL28B polymorphisms with the response to peginterferon plus ribavirin combined therapy in Polish patients infected with HCV genotype 1 and 4. Hepat Mon. 2013;13(11):e13678
   Google Scholar
• Sporea I, Popescu A, Curescu M, et al. The correlation of Il28B genotype with sustained virological response in Romanian patients with chronic hepatitis C. Hepat Mon. 2011;11(12):975–979
   Web of Science ®Google Scholar
• Tolmane I, Rozentale B, Keiss J, et al. Interleukin 28B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat Res Treat. 2012;2012:ID324090
   Google Scholar
• Alsaran K, Sabry A, Shaheen N. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: A single Saudi center experience. Int Urol Nephrol. 2011;43:865–873
   PubMed Web of Science ®Google Scholar
• Khedmat H, Amini M, Ghamar-Chehreh ME, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl. 2014;25(1):1–8
   PubMedGoogle Scholar
• Ahn SB, Jun DW, Kim SG, et al. Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. Eur J Intern Med. 2015;26(4):292–296
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009, 461:798–801
   PubMed Web of Science ®Google Scholar
• Hardy J, Singleton A. Genome wide association studies and human disease. N Engl J Med. 2009;360:1759–1768
   PubMed Web of Science ®Google Scholar